Oxitone Medical

Company Overview

Snapshot

Founded in May 2010 by Leon Eisen and Ofer Harpak, Oxitone Medical operates with 1–10 employees. The company has raised a total of $9.2M across 4 funding rounds from 4 investors. In September 2017, the FDA cleared Oxitone's wrist-worn pulse oximeter for remote patient monitoring, marking a significant regulatory milestone.

Business overview

Oxitone Medical develops the Oxitone 1000M pulse oximeter, an FDA-cleared medical device designed for continuous monitoring and automatic flagging of critical medical issues in patients with severe chronic diseases. The device utilizes wrist-worn sensors to deliver real-time readings of SpO2, pulse rate, HRV, motion, and skin temperature to the cloud. It provides actionable insights such as hypoxia index, apnea index, activity index, sleep efficiency, and physiological stress, focusing on conditions like acute respiratory failure, physiological stress, and sleep disorders. The company operates within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Medical Devices, serving markets in North America and Europe.

Strategic signal

In June 2020, Ascom UMS selected Oxitone Medical as a wearable solution for continuous remote monitoring of COVID-19 patients. This partnership highlights the increasing demand for remote patient monitoring solutions, particularly in response to global health crises, and validates Oxitone's technology as a critical tool for managing chronic diseases and emerging health challenges.

Company Intelligence Q&A

What is Oxitone Medical's primary product?

Oxitone Medical's primary product is the Oxitone 1000M pulse oximeter, an FDA-cleared wearable wrist monitor for continuous monitoring of patients with severe chronic diseases.

When did Oxitone Medical receive FDA clearance for its device?

Oxitone Medical's wrist-worn pulse oximeter received FDA clearance for remote patient monitoring in September 2017.

Which company selected Oxitone Medical for COVID-19 patient monitoring?

In June 2020, Ascom UMS selected Oxitone Medical as a wearable solution for continuous remote monitoring of COVID-19 patients.

Which investors participated in Oxitone Medical's Seed round?

In March 2013, Oxitone Medical received funding from Gefen Biomed Investments and GE Ventures during its Seed round.

Has Oxitone Medical received any grants?

In January 2015, Oxitone Medical secured a grant from the Israel Innovation Authority.